Background: To compare health care utilization and cost by asthma severity and type of health insurance in Thailand. Methods: A retrospective cohort study using an electronic database was conducted in patients with asthma. Patients who were diagnosed with asthma from 2009 to 2011, had at least two subsequent health care encounters for asthma during the first six months after the first asthma diagnosis, and had at least 90 days of follow-up were included. The primary outcome was direct health care costs of inpatient and outpatient care. We compared outcomes between groups on the basis of a proxy of severity (mild/moderate severe asthma vs. high severe asthma) and type of health insurance using a multivariable generalized linear model. Covariates such as Patients' demographic characteristics, comorbidities, and concurrent medications were included in the model. Results: Among 1982 patients included, the average age was 40.3 Ϯ 24.0 years, with 60.7% being males. A total of 1936 patients had mild/moderate severe asthma, whereas 46 patients had high severe asthma. There were 1293 patients under the Universal Coverage Scheme, 264 patients under Social Security Insurance, and 626 patients under the Civil Servant Medical Benefit Scheme (CSMBS). The average annual cost per patient was $598 Ϯ $871. In adjusted analyses, the health care cost of patients with high severe asthma was $71 higher than that of patients with mild/moderate severe asthma (95% confidence interval $À131 to $274). The cost of patients under the CSMBS was $110 (95% confidence interval $29-$191) higher than that of patients under Universal Coverage Scheme. Conclusions: Health care costs of patients with asthma were substantial and were higher in patients with high severe asthma and patients under the CSMBS.
Background
Asthma is a common chronic respiratory disease that affects 300 million people worldwide [1] [2] [3] . Prevalence, health care utilization, and costs of patients with asthma are substantial. An estimated 8.2% of the US population has asthma [4] , whereas the prevalence of asthma was 5.1%, 9.1%, and 10.6% for China, Malaysia, and Singapore, respectively [5] . In addition, asthma has been shown to be an important health problem in Thailand. It is estimated that around 12.2% of the Thai population has asthma, which equates to approximately 8.1 million people [5] . The rate of asthma-related emergency visits, hospitalization, and work absences in Thailand was 22%, 15%, and 24%, respectively [6] . The average cost per hospitalization was $135 per patient [7] .
To date, general practice for treating patients with asthma in Thailand follows the Global Initiative for Asthma guideline, which recommends treatments for patients with asthma based on patients' current treatments as so-called asthma treatment steps. Briefly, the Global Initiative for Asthma guideline classifies treatment steps as step 1 through step 5. Treatment step 1 corresponded to short-acting beta-agonists (SABAs); step 2 corresponded to low-dose inhaled corticosteroids (ICSs), leukotriene modifiers, low-dose methylxanthines, or mast-cell stabilizers; step 3 corresponded to low-dose ICSs plus long-acting betaagonists (LABAs) or leukotriene modifiers or methylxanthines or medium/high-dose ICSs; step 4 corresponded to medium/highdose ICSs plus LABAs or leukotriene modifiers or methylxanthines; and step 5 corresponded to add-on anti-immunoglobulin E inhibitor or chronic low-dose oral corticosteroids. The Global Initiative for Asthma treatment recommendation is slightly different between children with asthma and adult patients [8] .
To appropriately allocate limited health care resources, understanding current patterns of health care utilization and cost of asthma is very important. A US study [9] indicated that direct medical cost in patients with severe asthma was around 3.5 times higher than that in patients with mild asthma. Studies from Canada [10] and Korea [11] also revealed that costs of care in patients with more severe asthma were higher than in those with less severe asthma. Not only severity of asthma impacts health care utilization, the availability and design of the health insurance benefit for individuals can also affect health care utilization. A study [12] from the United States indicated that insured children with asthma were more likely than uninsured patients to receive ICS. Another study from Puerto Rico [13] indicated that children with asthma who had private insurance were more likely than those with public insurance to receive asthma controller medications.
Currently, little is known about specific patterns of asthma medication use, total health care resource utilization, and cost of asthma management in Thailand. Although several Western studies have reported patterns of health care utilization among patients with asthma, they are not applicable to the Asia-pacific region and specifically to Thailand because of differences in patterns of asthma care, physician practice, and the health care system. Patterns of health care utilization and cost obtained in this study will be important information for health care policymakers for allocating health care resources for patients with asthma in Thailand. Moreover, the findings could be used as key input parameters in economic evaluations of interventions for patients with asthma. The objective of this study was to compare health care utilization and cost by asthma severity and type of health insurance in Thailand.
Methods

Study Design and Data Source
This retrospective cohort study was conducted using data from a university-affiliated hospital in Thailand. The study protocol was approved by the institutional review board of the hospital. Electronic hospital databases including inpatient and outpatient diagnosis databases, dispensing databases, and charge databases were used. Inpatient and outpatient databases contained information on sex, health insurance, date of birth, and International Statistical Classification of Diseases, 10th Revision (ICD-10) codes. Dispensing databases included medication name, regimen, and amount of medication per prescription. In addition, charge databases contained data on medication, laboratory, medical service, and other service charges. All patient records were anonymous and de-identified before analysis.
Patients and Study Period
Only patients continually receiving care at this hospital during the study period were included. They had to meet the following inclusion criteria: 1) diagnosed with asthma (ICD-10 code of J45.x) between January 2009 and December 2011; 2) have at least two subsequent health care encounters with an ICD-10 code of J45.x during the first 6 months after the first coded diagnosis; and 3) had at least 90 days of follow-up. These two latest criteria were set to ensure the continuity of care of the patients. The patients who met the criteria were likely to receive the treatment for asthma at the study site [14] [15] [16] . The index date for each patient was the first diagnosis date during the study period. All included patients were tracked from the index date until the end of December 2011.
Assessing Severity of Asthma
We could not directly measure the severity of asthma because of the nature of retrospective database analysis. Thus, we adopted an algorithm developed by Schatz et al. [17] in 2006, which has been widely used in determining asthma severity using pharmacy claim data [18] [19] [20] , to determine the severity of asthma in each patient. Asthma severity was defined by the number of oral corticosteroids or SABAs during 1 year before the index date. Patients were categorized into the mild/moderate severe group (patients who received SABAs r13 times or received oral steroids r2 times in a past year) and the high severe group (patients who received SABAs 413 times or received oral steroids 42 times and received SABA 5-13 times in a past year) [17] .
Health Insurance in Thailand
In Thailand, there are three major types of health insurance that provide coverage; these are 1) the Civil Servant Medical Benefit Scheme (CSMBS); 2) Social Security Insurance (SSI); and 3) the Universal Coverage Scheme (UC scheme). The CSMBS predominantly covers government officers and their dependents and pays health care facilities on a fee-for-service basis. The SSI predominantly covers private sector employees and is funded through contributions from the government, employers, and employees. Payments for those with SSI were capitation for outpatient visit and based on diagnosis related groups for inpatient visits. The UC scheme provides health care coverage to all remaining Thai citizens who are not covered by the CSMBS or the SSI and is funded by the Thai government. Payment for those with the UC scheme was capitation for outpatient visits and based on diagnosis related groups for inpatient visits.
Outcome Measures
The primary outcome measure was annual health care cost per patient. Secondary outcome measures were annual number of hospitalizations and outpatient visits. Outpatient visits included both urgent and nonurgent preventive care visits. Annual health care costs were calculated using direct medical inpatient and outpatient costs because the study was conducted from the health care payer perspective. Costs included medication, medical service, diagnosis, laboratory, and other service costs. Costs were calculated on the basis of the conversion of charge to cost by using the ratio of cost to charge [21] . Costs were converted to 2011 value using the consumer price index. The exchange rate of Thai baht to US dollar was US $1 ¼ 30.59 Thai baht [22] .
Statistical Analyses
Descriptive analysis was used to describe baseline characteristic and outcomes. Severity of disease and health insurance schemes were used to compare groups. Kruskal-Wallis test or Wilcoxon rank sum test was used to determine differences in outcomes among groups. Multivariable generalized linear model (GLM) with gamma distribution and log link was used to determine the difference in average health care cost, whereas multivariable negative binomial regression was used to determine the difference in the number of hospitalizations among groups with different severity and health insurance. The GLM with gamma distribution and log link was used because our cost data were skewed. There are several methods that have been used to handle the issue such as log non-linear regression with and without Duan, smearing correction, median regression, and GLM with gamma distribution and log link function. We selected the
GLM because a previous study indicated that the GLM provided the best estimates of cost data analysis [23] . For the number of hospitalizations, which was count data, Poisson regression or negative binomial regression was used to analyze such data. However, an important limitation of Poisson regression is that the data must not be overdispersed. In our data, we found the overdispersion of data. Therefore, we selected negative binomial regression to analyze our data.
Health insurance was included as a covariate in the model to determine the effect of severity of disease on cost and hospitalization, whereas the severity of disease was also included as a covariate in the model to determine the effect of health insurance on cost and hospitalization. Other potential covariates used in the models included age, sex, Charlson's comorbidity index (as a proxy of health status of patients), comorbidities (gastroesophageal reflux disease, obstructive sleep apnea, chronic sinusitis, obesity, respiratory infection, and concurrent medications [ICSs, inhaled LABAs, SABAs, xanthine oxidase inhibitors, oral LABAs, leukotriene-modifying agents, and inhaled anticholinergic medications]). All potential covariates were selected on the basis of our literature review and clinical plausibility. We classified the potential covariates into three groups as 1) demographic data (age, sex, and health insurance); 2) comorbidities; and 3) concurrent medications. For demographic data, age, sex, and health insurance are usually related to outcomes. For comorbidities, we selected the covariates on the basis of previous literature [16, 24, 25] , which indicated that gastroesophageal reflux disease [26, 27] and obesity [28, 29] are likely to be associated with asthma outcomes, whereas others are respiratory diseases that are likely to be associated with asthma exacerbation and hospitalization. For concurrent medications, we included all medications used to treat asthma as covariates. The medications have been used to treat asthma; thus, they definitely are related to asthma outcomes.
Stepwise forward selection with inclusion criteria of P o 0.2 was used to select covariates into the models. Outliers of the data were determined by standardized residual approach. Data that had a standardized residual of 3 or more were classified as outliers [30] . Outlier data were excluded from final analysis.
Results
A total of 1982 patients were included in this study (Fig 1) . Patients were an average of 40.3 Ϯ 24.0 years of age, with 60.7% being males. During the study period, 1936 (97.7%) patients were categorized into the mild/moderate severe asthma group but only 46 (2.3%) patients were categorized into the high severe asthma group. More than half (57.9%) were under the UC scheme. Most high severe group patients (31 of 46 or 1.6% of total patients) were under the UC scheme, whereas only 9 of 46 patients (0.5% of total patients) were under the CSMBS (Table 1) .
Overall Health Care Utilization and Cost
Most patients received ICSs (78.1%) and short-acting beta-2 agonists (77.4%). Among patients receiving SABAs, 9.3% received oral SABAs alone, 12.8% received inhaled SABAs alone, and 77.9% received both inhaled and oral SABAs. The number of patients who received each type of asthma medication is shown in Figure 2 . 
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The annual average cost was calculated for only 1958 patients. A total of 24 patients were excluded in our cost analysis because they were classified as outliers. The annual average health care cost was $598 Ϯ $871. Table 2 ). The median and IQR for inpatient costs were all zero because of a number of patients with no hospitalization. A major driver of total direct medical cost was medication cost, which accounted for 62.8% of total cost.
Health Care Utilization, Costs by Asthma Severity
Most patients (95.7%) with high severe asthma received ICSs, whereas about three-fourth (77.7%) of patients with mild/ moderate severe asthma did. Percentages of patients receiving inhaled LABAs were 63.0% and 37.7% in patients with high severe and mild/moderate severe asthma, respectively (Fig 2) .
The annual average cost of health care in patients in the high severe group was higher than that of those in the mild/moderate severe group. The cost for patients in the high severe group was $658 Ϯ $414 (median [IQR] $598 [$267-$906]), whereas that for patients in the mild/moderate severe group was $596 Ϯ $879 (median [IQR] $332 [$149-$714]) (P ¼ 0.003). Similarly, the average number of outpatient visits for patients in the high severe group (10.78 visits) was higher than that for patients in the mild/ moderate severe group (8.56 visits). However, no statistically significant differences in the average number of inpatient visits and inpatient costs were found between groups (Table 2) . According to multivariable analysis, annual average health care cost for patients in the high severe group was $71 higher than that for Figure 2 -Percentages of patients receiving asthma medications by severity of disease and health insurance schemes. CSMBS, Civil Servant Medical Benefit Scheme; ICS, inhaled corticosteroid; LABA, long-acting beta-agonist; SSI, Social Security Insurance; UC, Universal Coverage Scheme. *Short-acting beta-agonists included both inhaled and oral forms.
patients in the mild/moderate severe group (95% confidence interval [CI] $À131 to $274). The rate of hospitalization between the two groups was not significantly different (Table 3) .
Health Care Utilization, Costs by Health Insurance
The percentage of patients under the CSMBS receiving inhaled LABAs (60.5%) was higher than that of patients under the UC scheme (29.1%) and the SSI (28.3%). Patients under the CSMBS (31.5%) received leukotriene-modifying agents more than did patients under the UC scheme (20.1%) and the SSI (10.7%). The use of other asthma medications was not different among the three health insurance schemes (Fig 2) .
The , respectively. The outpatient costs and the number of outpatient visits of patients under the CSMBS were also more than those of patients under the UC scheme and SSI. However, the annual average cost of inpatient care and the number of inpatient stays were similar among those patients (Table 4 ). According to multivariable regression, annual cost in patients under the CSMBS was higher than that in patients under the UC scheme ($110 [95% CI $29-$191]), whereas the cost in patients under the SSI was lower than that in patients under the UC scheme (À$39 [95% CI $À124 to $44]). The annual risk of hospitalization was not significantly different by health insurance (Table 3 ).
Discussion
Our findings provide estimates of the health care utilization and costs associated with asthma in Thailand. We found that there were differences in terms of both health care utilization and overall costs between patients, with those in the high severe group and patients covered by the CSMBS having higher costs, primarily as a result of differences in medications used and outpatient visits. To our knowledge, this study is the first study in Asia that provides health care utilization and costs based on asthma severity and health insurance. This information can be valuable for clinicians and policymakers in efficiently planning and allocating resources to achieve optimal care in patients with asthma at the population level. In addition, it might point to gaps in care between patients based on insurance status and allow for improvements in the quality of asthma care.
Health care resource utilization of patients in the high severe group was higher than that of patients in the mild/moderate severe group. The health care cost of patients in the high severe CI, confidence interval, CSMBS; Civil Servant Medical Benefit Scheme, SSI; Social Security Insurance; UCS, Universal Coverage Scheme. * Adjusted for health insurance, sex, age, inhaled long-acting betaagonists, leukotriene-modifying agent, inhaled anticholinergic antagonist, and inhaled corticosteroid. † Adjusted for health insurance, sex, age, chronic sinusitis, xanthine oxidase inhibitor, and short-acting beta-agonist. ‡ Adjusted for severity of disease, sex, age, inhaled long-acting beta-agonists, leukotriene-modifying agent, inhaled anticholinergic antagonist, and inhaled corticosteroid. § Adjusted for severity of disease, sex, age, chronic sinusitis, xanthine oxidase inhibitor, and short-acting beta-agonist. ( 2 0 1 6 ) 1 0 5 -1 1 1 group was $71 per year higher than that of patients in the mild/ moderate severe group. The differences in costs observed were likely because high severe group patients needed more medications than did mild/moderate severe group patients, including ICSs, inhaled LABAs, and inhaled anticholinergic medications, which were high-cost medications. High severe group patients also had more follow-up visits than did mild/moderate severe group patients. Our findings showed that high severe group patients needed to visit the outpatient department about 2.2 times per year more often than did mild/moderate severe group patients. Similarly, high severe group patients were likely to be hospitalized more often than mild/moderate severe group patients without significant difference. Results from other studies also showed that patients with high severe asthma had a higher risk to be hospitalized and for emergency department visit, which cause the increase in health care resource utilization and cost [6, 31, 32] .
V A L U E I N H E A L T H R E G I O N A L I S S U E S 9 C
The annual direct medical cost incurred in patients with asthma was $598 per patient. This study finding was different from the result from a previous study [33] that reported that average direct cost in patients with asthma was $246 per patient for a provincial hospital but was similar to the result for a university hospital, which was $548 per patient. The differences were likely due to types of hospitals. Regional and university hospitals usually serve patients with more complicated diagnosis and treatment. Those might cause higher cost of care in patients with asthma.
Compared with the cost of care of other respiratory diseases, the cost of asthma care shown in our study was lower than the health care cost of chronic obstructive pulmonary disease (COPD). A previous study reported that the cost of COPD in Thailand was $1952 per patient per year [34] . It was likely due to differences in the presence of coexisting conditions when comparing patients with COPD to patients with asthma. COPD usually occurs in elderly patients who may have a large number of comorbidities and receive many medications. In contrast, asthma may occur in a much younger population, which has less coexisting diseases, which may influence the overall cost of health care in these patients
The health care cost in patients under the CSMBS was $110 per year higher than that in patients under the UC scheme. Results of the present study showed that patients under the CSMBS received more inhaled LABAs and leukotriene-modifying agents, which are high-cost medications, than did patients under the UC scheme and SSI. This is similar to a previous report from the World Health Organization that revealed that patients under the CSMBS received high-cost interventions more often than did patients under the UC scheme [35] , which led to higher cost of care. It was likely due to the mechanisms of reimbursement because the hospitals are fully reimbursed for care provided to patients under the CSMBS, whereas the payment mechanism of other insurance schemes was capitation. These might result in health care providers using more high-cost medications and procedures in patients under the CSMBS. However, because the UC scheme payment mechanism was capitation, physicians are prone to be vigilant regarding the medications prescribed compared with the case of patients under the CSMBS. Importantly, it can lead to disparities in care for patients with asthma.
Some limitations of this study should be recognized. First, our study was conducted in a university-affiliated hospital. This, however, does not compromise the generalizability of the study because the study setting shares similar characteristics with other tertiary care hospitals. Second, these findings relied on electronic databases, which can lead to misclassification. Third, we would be unable to observe any care that was provided outside of the university-affiliated hospital and thus may underestimate health care utilization and costs. Fourth, we assessed Table 4 Average annual direct medical costs and health care utilization by health insurance. Costs were presented in US dollars.
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asthma severity of each patient using electronic database. The actual severity could not be captured within the database. Thus, we need to use a proxy to assess the severity instead. The severity assessed by the proxy might be different from the actual severity. However, the algorithm used as a proxy in this study is widely accepted [36] [37] [38] . This might not substantially affect our findings. Last, the outpatient outcomes in this study included both emergency and regular visits because the database did not separately record emergency visits and regular visits.
Conclusions
The health care cost and utilization in patients with asthma were substantial and were higher in high severe group patients and patients under the CSMBS. More effective policies or strategies should be developed to appropriately allocate health care resources and diminish inequity in the management of asthma. For example, national health care policymakers should consider allocating more budgets and resources to those hospitals that serve more number of patients with asthma under the CSMBS or those that serve patients with highly severe asthma such as regional hospitals or teaching hospitals.
